Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838463 | 0.89 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6838024 | 0.83 | ADORA2A (0.65) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6379616 | 0.82 | ADORA2A (0.62) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6379846 | 0.82 | ADORA2A (0.62) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6380393 | 0.82 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6462442 | 0.82 | ADORA2A (0.64) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL6385386 | 0.82 | ADORA2A (0.59) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14589604 | 0.78 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL16311915 | 0.78 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14508548 | 0.78 | ADORA2A (0.77) | ADORA2AADORA3ADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501850-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | ADORA2A 174/4885ADORA3 170/4885ADORA1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.